Catalog Home Page

Abacavir pharmacogenomics

Phillips, E.J. and Mallal, S. (2014) Abacavir pharmacogenomics. In: Murray, M.F., Babyatsky, M.W., Giovanni, M.A., Alkuraya, F.S. and Stewart, D.S., (eds.) Clinical Genomics: Practical Applications in Adult Patient Care. McGraw-Hill Professional.

Google Books Preview:
*Open access. Some pages may not be available


Abacavir is a nucleoside reverse transcriptase inhibitor used in combination therapy for the treatment of the human immunodeficiency virus type 1 (HIV-1) that has been associated with a hypersensitivity reaction in approximately 8% of those starting the drug.

Abacavir hypersensitivity reaction is characterized by greater than or equal to two progressive symptoms typically starting from the second week of therapy (median 9 days) with fever, malaise, nausea, vomiting, diarrhea, and later mild-to-moderate skin rash (present in 70% of patients).

Symptoms of abacavir hypersensitivity resolve rapidly with 24 to 72 hours after drug discontinuation.

A previous clinical history compatible with abacavir hypersensitivity is a contraindication to future rechallenge as severe morbidity and even mortality characterized by hypotension and shock has been described.

Item Type: Book Chapter
Murdoch Affiliation: Institute for Immunology and Infectious Diseases
Publisher: McGraw-Hill Professional
Copyright: © 2014 by McGraw-Hill Education
Item Control Page Item Control Page